Feb. 13, 2020 Price forecast | 2 weeks: -0.62% | 1 month: -0.62% | 3 months: 0.14%


CRL stock forecast

Our latest prediction for Charles River Laboratories International, Inc.'s stock price was made on the Feb. 13, 2020 when the stock price was at 172.30$.

In the short term (2weeks), CRL's stock price should underperform the market by -0.62%. During that period the price should oscillate between -5.35% and +3.22%.

In the medium term (3months), CRL's stock price should outperform the market by 0.14%. During that period the price should oscillate between -12.21% and +8.97%.


About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

At the moment the company generates 2621M USD in revenues.

On its last earning announcement, the company reported a profit of 5.07$ per share.

The book value per share is 24.61$

Charles River Laboratories International, Inc. website


Three months stock forecastFeb. 13, 2020


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
2621M 36.60% 351M 13.40% 252M 5.07 - - 50M 24.61 481M -141M 340M